TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03424564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral Tablet
Study: NCT01589796

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: injection of 20ml of Ropivacaine 0.5% in the proper place once it is identified

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: injection of 20ml of Ropivacaine 0.5% in the proper place once it is identified
Study: NCT00005984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: intravenously over 2 hours on day 1 and on days -7 and -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Beginning on Day 1, subcutaneous (SQ) daily administration in the absence of unacceptable toxicity or disease progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Patients receive the PBSC transplantation on day 0.
Study: NCT03910686

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation and cognitive behavioral therapy
Description: Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation and cognitive behavioral therapy
Description: Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
Study: NCT00005984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: total body irradiation twice a day on days -4 through -1
Study: NCT01254253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention, PCI
Description: PCI was performed using standard techniques for CTO.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention, PCI
Description: PCI was performed using standard techniques for CTO.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention, PCI
Description: PCI was performed using standard techniques for CTO.
Study: NCT03646604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib (ABT-494)
Description: Upadacitinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib (ABT-494)
Description: Upadacitinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib (ABT-494)
Description: Upadacitinib will be administered orally.
Study: NCT03910686

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial magnetic stimulation and cognitive behavioral therapy
Description: Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
Study: NCT04393337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gestational Age Chart Method
Description: The endotracheal tube insertion depth is obtained by the gestational age chart

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal-Tragus Length Method
Description: The endotracheal tube insertion depth is obtained by the nasal-tragus method formula
Study: NCT03646604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib (ABT-494)
Description: Upadacitinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib (ABT-494)
Description: Upadacitinib will be administered orally.
Study: NCT00414635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermitent Dosing
Description: Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. .

Intervention type: DRUG
Group type: OTHER
Intervention: Intermitent Dosing
Description: Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. .
Study: NCT03534609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutronic Genius System
Description: Treatment of the neck using the Lutronic Genius System
Study: NCT00991861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41007 o.d.
Description: Once daily, topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41007 b.i.d.
Description: Twice daily, topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS106521
Description: Twice daily, topical application
Study: NCT04301375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab and trastuzumab FDC subcutaneous
Description: Pertuzumab and trastuzumab FDC subcutaneous, A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg; day 1 of each 3 week cycle during 5 neoadjuvant cycles and 13 adjuvant cycles if complete response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2, day 1,8,15 of each 3 week cycle during 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM1
Description: 3,6 mg/kg, 14 adjuvant cycles if not complete response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Adjuvant endocrine therapy will be administered as per local practice and according to recognized clinical practice guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission surgery
Description: Omission of surgery and sentinel lymph node dissection in patients with HER2-E and ERBB2 high breast cancer who achieving a complete response following standard anti-HER2-based neoadjuvant therapy with paclitaxel/trastuzumab/pertuzumab
Study: NCT04107948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity program
Description: Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42), Haute-Loire (43) or Ardèche (07) for 2 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Advice and recommendations of physical activity at home
Description: Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
Study: NCT03010917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish Oil with ethanol and placebo ethanol infusions
Description: Fish Oil with ethanol and placebo ethanol infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with ethanol and placebo ethanol infusions
Description: Placebo with ethanol and placebo ethanol infusions
Study: NCT02474446

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 150,000 IU of Vitamin D3 Oral solution
Study: NCT00777140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.~Bolus + 72h perfusion of saline solution for the placebo group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deferoxamine
Description: Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.~Bolus + 72h perfusion of saline solution for the placebo group.
Study: NCT00659412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular
Study: NCT02946437

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Description: Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.

Intervention type: DEVICE
Group type: OTHER
Intervention: MIRUS™System
Description: The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRUS™System
Description: The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.
Study: NCT00003994

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT02423850

Intervention type: DEVICE
Intervention: 3D Wound Assessment Monitor (WAM) camera
Description: Three-dimensional wound measurement (2D area, 3D area, perimeter, volume) using 3D-WAM camera
Study: NCT04683627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium active topical patch
Description: A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: A placebo patch without diclofenac sodium was used for the placebo arm.
Study: NCT01820299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract
Description: All patients enrolled to the study will take Grape Seed Extract alone for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together. Patients will take Vitamin D once at a day at 4000 IU.
Study: NCT00656357

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SYN117 Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN117 80 mg
Description: SYN117 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN117 160 mg
Description: SYN117 160 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 10mg
Description: IV Cocaine 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 10mg
Description: IV Cocaine 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 20mg
Description: IV Cocaine 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 20mg
Description: IV Cocaine 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine 40mg
Description: IV Cocaine 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine 40mg
Description: IV Cocaine 40mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: IV Cocaine Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: IV Cocaine Placebo
Study: NCT01179724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose proton pump inhibitor
Description: IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H2RB
Description: IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month
Study: NCT03860792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Three-month 1:1 ketogenic diet intervention (approximately 70% fat, \<10% carbohydrate, and 20% protein).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Lifestyles Changes Diet
Description: Three-month diet intervention that is low in fat and cholesterol, high in fruits, vegetables, and whole grains, and moderate in protein.
Study: NCT04427319

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-alanine
Description: 7 days of consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: wheat semolina
Description: 7 days of consumption
Study: NCT03623113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCC intervention
Description: Structured training and education i basic carbohydrate counting principles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABC-ACC intervention
Description: Structured training and education i advanced carbohydrate counting principles including the use of a automated bolus calculator carbohydrate

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dietary education
Description: Personalized individual dietary counselling based on overall meal planning, dietary guidelines and the patient's need and preferences
Study: NCT03866070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Two exercises will be done to strengthen the external rotation (using elastic bands): standing with 90 degrees of shoulder abduction and elbow flexion and also in standing with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. Dumbbell exercises will be performed through 4 exercises: flexion in the horizontal plane of 135º, external rotation in lateral decubitus, horizontal abduction with external rotation, and extension in prone position. There will be 5 repetitions each exercise of 3 seconds each, with 2 minutes of rest between exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Two exercises will be done to strengthen the external rotation, using elastic bands. The first, standing, with 90 degrees of shoulder abduction and elbow flexion. The second, also in standing, with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. The band will be subject to a surface, at an equal distance from the subject's elbow to the ground. The repetitions will last one second in concentric external rotation and two seconds in eccentric external rotation, with a rest of 30 seconds between series.
Study: NCT04333563

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive airway pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous positive airway pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV NAVA
Description: Non-invasive neurally adjusted ventilatory assist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV NAVA
Description: Non-invasive neurally adjusted ventilatory assist
Study: NCT02564666

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telephone counseling
Description: regular telephone counseling for compliance and advese event
Study: NCT05118971

Intervention type: DIAGNOSTIC_TEST
Intervention: muscle activation of the vastus lateralis, vastus medialis, gluteus medius, tibialis anterior, rectus abdominis and paravertebral muscles
Description: understand the pattern of muscle activation during modalities used in this study with the selected population, it becomes extremely important, allowing the quantification of muscle functions and, therefore, prescribing exercises more adequately to achieve therapeutic goals.

Intervention type: DIAGNOSTIC_TEST
Intervention: muscle activation of the vastus lateralis, vastus medialis, gluteus medius, tibialis anterior, rectus abdominis and paravertebral muscles
Description: understand the pattern of muscle activation during modalities used in this study with the selected population, it becomes extremely important, allowing the quantification of muscle functions and, therefore, prescribing exercises more adequately to achieve therapeutic goals.

Intervention type: DIAGNOSTIC_TEST
Intervention: muscle activation of the vastus lateralis, vastus medialis, gluteus medius, tibialis anterior, rectus abdominis and paravertebral muscles
Description: understand the pattern of muscle activation during modalities used in this study with the selected population, it becomes extremely important, allowing the quantification of muscle functions and, therefore, prescribing exercises more adequately to achieve therapeutic goals.

Intervention type: DIAGNOSTIC_TEST
Intervention: muscle activation of the vastus lateralis, vastus medialis, gluteus medius, tibialis anterior, rectus abdominis and paravertebral muscles
Description: understand the pattern of muscle activation during modalities used in this study with the selected population, it becomes extremely important, allowing the quantification of muscle functions and, therefore, prescribing exercises more adequately to achieve therapeutic goals.
Study: NCT02780401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given ID
Study: NCT04004897

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optic nerve sheath diameter measurement
Description: Optic nerve sheath diameter measurement is performed with a linear ultrasound probe placed over the eyelid.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optic nerve sheath diameter measurement
Description: Optic nerve sheath diameter measurement is performed with a linear ultrasound probe placed over the eyelid.
Study: NCT04782401

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided genicular nerve block + exercise treatment
Description: This method was used to inject a total of 6 mL of lidocaine plus 40 mg of triamcinolone (TA) at 3 separate target sites: the superior lateral, superior medial, and inferior medial genicular nerves plus exercise treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy + exercise treatment
Description: Ten sessions of hotpack as a surface warmer, TENS as a analgezic current, ultrasound therapy as a deep warmer and exercise treatment.
Study: NCT01776801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion
Description: Infusion studies are performed in daily clinical routine to measure cerebrospinal fluid resistance outflow. During this test ICP is slowly and securely raised. Investigators plan to analyze what are the consequences of this ICP rise in terms of autonomic system and hemodynamics.
Study: NCT00979901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast
Description: 10 mg montelukast tablet given once daily at bedtime for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: loratadine
Description: 10 mg loratadine tablet given once daily at bedtime for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo tablet given once daily at bedtime for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast/loratadine
Description: montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks